Cure8 research brief
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for appropriate care.
Adult patients with IBD who have respiratory symptoms, gastroenterologists, pulmonologists, and researchers studying the microbiome, immune pathways, or extraintestinal manifestations of IBD.
The article reviews mechanistic and clinical studies linking intestinal barrier dysfunction and dysbiosis to altered immune signaling and lung involvement, highlighting microbial metabolites (for example short-chain fatty acids) and immune cell homing as potential regulatory nodes.
It also discusses drug-related pulmonary toxicity and the diagnostic challenge of distinguishing intrinsic pulmonary involvement from infection or treatment effects.
The authors call for prospective studies that combine measures of intestinal inflammation, circulating biomarkers, pulmonary phenotypes, and drug exposure to build a stratified diagnostic framework.
Practical takeaways: clinicians and researchers are encouraged to consider gut–lung interactions and microbial metabolites when evaluating lung symptoms in IBD, and to pursue more integrated studies; this is a review of existing research rather than new trial results.
This record is a journal review (abstract-level summary provided). It synthesizes existing basic and clinical studies but does not present new primary trial results; authors note a lack of prospective studies linking intestinal activity, biomarkers, pulmonary phenotypes, and drug exposure.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Environmental pollutants are increasingly linked to Crohn's disease risk, especially when exposures occur in early life. Understanding these links may help explain rising IBD rates and guide future prevention research.
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
